QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 upward-trajectory-for-biotechpharma-ma-sector-trends-towards-pre-pandemic-levels-forecasts-positive-for-2024

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 bill...

 an-oversold-gold-miner-with-strong-fundamentals--its-relative-strength-index-is-below-20-and-its-piotroski-f-score-is-8

Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attent...

Core News & Articles

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"...

Core News & Articles

-Bloomberg

 cantor-fitzgerald-reiterates-neutral-on-reata-pharmaceuticals-maintains-172-price-target

Cantor Fitzgerald analyst Charles Duncan reiterates Reata Pharmaceuticals (NASDAQ:RETA) with a Neutral and maintains $172 pr...

 citigroup-downgrades-reata-pharmaceuticals-to-neutral-raises-price-target-to-1725

Citigroup analyst Yigal Nochomovitz downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Buy to Neutral and raises the price ...

 barclays-downgrades-reata-pharmaceuticals-to-equal-weight-raises-price-target-to-172

Barclays analyst Carter Gould downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Overweight to Equal-Weight and raises the ...

 baird-maintains-outperform-on-reata-pharmaceuticals-raises-price-target-to-173

Baird analyst Brian Skorney maintains Reata Pharmaceuticals (NASDAQ:RETA) with a Outperform and raises the price target from...

 ladenburg-thalmann-downgrades-reata-pharmaceuticals-to-neutral-raises-price-target-to-1725

Ladenburg Thalmann analyst Matthew Kaplan downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Buy to Neutral and raises the ...

 jefferies-downgrades-reata-pharmaceuticals-to-hold-raises-price-target-to-1725

Jefferies analyst Maury Raycroft downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Buy to Hold and raises the price target...

 crude-oil-edges-higher-colgate-palmolive-posts-upbeat-earnings

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Friday. The Dow tr...

 why-avantor-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Gainers Unique Fabricating, Inc. (NYSE: UFAB) shares jumped 113% to $0.4605 after gaining 12% on Thursday.

 dow-surges-250-points-exxon-mobil-earnings-miss-expectations

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 250 points on Friday. The Dow traded up 0....

 stifel-downgrades-reata-pharmaceuticals-to-hold-raises-price-target-to-1725

Stifel analyst Annabel Samimy downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Buy to Hold and raises the price target fr...